ברפטובי 75 מ"ג - Braftovi 75 mg

BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic MelanomaEncorafenib is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)Encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an approved test after prior therapy.BRAF V600E Mutation-Positive metastatic non-small cell lung cancer (NSCLC)Encorafenib is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma with a BRAF V600E mutation, as detected by an approved test.